178 related articles for article (PubMed ID: 29909589)
1. "It Was Not My Aim to Sleep There": The Impact of Timing and Location of Sex on Adherence to Coitally-Dependent HIV Pre-exposure Prophylaxis.
Scorgie F; Stadler J; Baron D; Ju S; Ikaneng T; Mabude Z; Makgopa S; Malefo MA; Manenzhe KN; Mazibuko T; Ntjana H; Nkala B; Palanee-Phillips T; Gray G; Rees H; Delany-Moretlwe S
AIDS Behav; 2018 Nov; 22(11):3692-3704. PubMed ID: 29909589
[TBL] [Abstract][Full Text] [Related]
2. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
3. Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.
Minnis AM; van der Straten A; Salee P; Hendrix CW
AIDS Behav; 2016 Jul; 20(7):1541-8. PubMed ID: 25969178
[TBL] [Abstract][Full Text] [Related]
4. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial.
Friedland BA; Stoner M; Chau MM; Plagianos MG; Govender S; Morar N; Altini L; Skoler-Karpoff S; Ahmed K; Ramjee G; Monedi C; Maguire R; Lähteenmäki P
AIDS Behav; 2016 Nov; 20(11):2565-2577. PubMed ID: 26204987
[TBL] [Abstract][Full Text] [Related]
5. Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".
Montgomery ET; van der Straten A; Stadler J; Hartmann M; Magazi B; Mathebula F; Laborde N; Soto-Torres L
AIDS Behav; 2015 May; 19(5):784-93. PubMed ID: 25416076
[TBL] [Abstract][Full Text] [Related]
6. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa.
van der Straten A; Stadler J; Montgomery E; Hartmann M; Magazi B; Mathebula F; Schwartz K; Laborde N; Soto-Torres L
PLoS One; 2014; 9(2):e89118. PubMed ID: 24586534
[TBL] [Abstract][Full Text] [Related]
7. Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.
MacQueen KM; Dlamini S; Perry B; Okumu E; Sortijas S; Singh C; Pillay D; Majors A; Jerome S; Watson S; Karim SA; Karim QA; Mansoor LE
AIDS Behav; 2016 Nov; 20(11):2682-2691. PubMed ID: 26945585
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
9. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
Montgomery ET; Noguchi LM; Dai JY; Pan J; Biggio J; Hendrix C; Isaacs K; Watts DH; Schwartz JL; Piper J; Beigi R
AIDS Behav; 2018 Feb; 22(2):402-411. PubMed ID: 28550377
[TBL] [Abstract][Full Text] [Related]
10. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
Mensch BS; Brown ER; Liu K; Marrazzo J; Chirenje ZM; Gomez K; Piper J; Patterson K; van der Straten A
AIDS Behav; 2016 Nov; 20(11):2654-2661. PubMed ID: 26906023
[TBL] [Abstract][Full Text] [Related]
11. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
Govender EM; Mansoor LE; Abdool Karim Q
AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
[TBL] [Abstract][Full Text] [Related]
12. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
13. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
[TBL] [Abstract][Full Text] [Related]
14. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
Velloza J; Heffron R
Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
[TBL] [Abstract][Full Text] [Related]
15. Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.
Matthews LT; Sibeko S; Mansoor LE; Yende-Zuma N; Bangsberg DR; Karim QA
PLoS One; 2013; 8(3):e56400. PubMed ID: 23472071
[TBL] [Abstract][Full Text] [Related]
16. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
17. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
Herold BC; Chen BA; Salata RA; Marzinke MA; Kelly CW; Dezzutti CS; McGowan I; Galaska B; Levy L; Piper JM; Hillier S; Hendrix CW
Clin Infect Dis; 2016 Feb; 62(3):375-382. PubMed ID: 26508513
[TBL] [Abstract][Full Text] [Related]
18. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
Friend DR; Kiser PF
Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
[TBL] [Abstract][Full Text] [Related]
19. Prevention, Partners, and Power Imbalances: Women's Views on How Male Partners Affected Their Adherence to Vaginal Microbicide Gels During HIV Prevention Trials in Africa.
Miller L; Morar N; Kapiga S; Ramjee G; Hayes R
J Acquir Immune Defic Syndr; 2020 Dec; 85(4):458-465. PubMed ID: 33136745
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]